PDE4A and asthma: Clinical studies have shown efficacy for orally administered PDE4 selective inhibitors on relevant asthma endpoints such as inhibition of allergen challenge [11,12] and exercise induced bronchoconstriction [13], as well as improvements in lung function [14].